UK markets closed

Ono Pharmaceutical Co., Ltd. (OPHLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
13.450.00 (0.00%)
At close: 01:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.45
Open13.45
Bid13.06 x 28000
Ask13.80 x 36100
Day's range13.45 - 13.45
52-week range12.66 - 19.83
Volume306
Avg. volume500
Market cap6.507B
Beta (5Y monthly)0.17
PE ratio (TTM)7.96
EPS (TTM)1.69
Earnings date31 Jul 2024
Forward dividend & yield0.52 (3.96%)
Ex-dividend date27 Sept 2024
1y target estN/A
  • PR Newswire

    ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

    ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow

  • Reuters

    Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion

    Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.

  • Reuters

    Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

    Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.